Loading
The GM-CSF receptor is what sargramostim switches on to speed the recovery of white cells after leukaemia chemotherapy and stem cell transplantation, and it is the signal that tumour vaccines such as talimogene use to recruit immune cells. This dossier gathers the 1 product (0 approved), 6 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A type I cytokine receptor whose beta chain activates JAK2 and STAT5; it drives proliferation and differentiation of granulocyte and macrophage precursors and activates dendritic cells.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | host% | Host target: GM-CSF receptor on white-cell precursors. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Withdrawn or failed |
|---|---|
| Recombinant granulocyte-macrophage colony-stimulating factor, injection 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Completed | A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease | - | ||
ANBL17P1 NCT03786783 | 2 | Positive | Newly diagnosed high-risk neuroblastoma: a pilot induction regimen adding the anti-GD2 antibody dinutuximab and GM-CSF to the standard five-cycle chemotherapy induction, followed by tandem transplant and radiotherapy, with unacceptable toxicity and feasibility as the primary endpoints | No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added. | |
ANBL1221 NCT01767194 | 2 | Positive | Children with relapsed, refractory or progressive neuroblastoma: irinotecan and temozolomide with either temsirolimus or the anti-GD2 antibody dinutuximab plus GM-CSF, randomised, then a non-randomised expansion of the dinutuximab arm | Objective response 52.9 percent with irinotecan, temozolomide and dinutuximab against 5.6 percent with temsirolimus in the randomised part; 41.5 percent across all 53 dinutuximab-treated patients with one-year overall survival of 84.9 percent. | |
| 2 | Completed | A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer | - | ||
| 2 | Recruiting | A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients With Metastatic Triple-Negative Breast Cancer | - | ||
| 1/2 | Recruiting | A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA) | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"GM-CSF receptor" OR ABSTRACT:"GM-CSF receptor" OR TITLE:"CSF2RA" OR ABSTRACT:"CSF2RA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GM-CSF receptor (CSF2RA), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/csf2ra.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/csf2ra.json. Licence CC BY-NC 4.0.